Apotex launches generic Sprycel
Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.
Aprotex is offering dasatinib tablets, a generic version of Sprycel.
The company has 180 days of exclusivity.
Dasatinib is a kinase inhibitor used to treat certain types of leukemia in adults and children 1 year of age and older, including cases where previous treatments were ineffective or tolerated.
[Read more: Ambio obtains FDA OK for generic Forteo for partner Apotex]
"Apotex continues to deliver best-in-class product launches, supporting patients on their journey to health,” said Christine Baeder, president of Apotex. “As the first generic manufacturer to launch dasatinib in the United States, we are proud to provide this high-quality, cost-saving option."